oltipraz

DRUG4 trials

Sponsors

Northwestern University, HK inno.N Corporation, PharmaKing

Conditions

Liver CirrhosisLiver FibrosisLung CancerNon-Alcoholic Fatty Liver DiseaseNon-alcoholic Fatty Liver Disease

Phase 1

Oltipraz in the Prevention of Lung Cancer in People Who Smoke

CompletedNCT00006457

Northwestern UniversityLung Cancer

Start: 2000-08-31End: 2004-04-30Updated: 2012-06-11

Phase 2

Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis

CompletedNCT00956098

HK inno.N CorporationLiver Cirrhosis, Liver Fibrosis

Start: 2006-02-28End: 2007-02-28Target: 81Updated: 2009-08-11

Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease

CompletedNCT01373554

PharmaKingNon-alcoholic Fatty Liver Disease

Start: 2011-05-31End: 2013-10-31Updated: 2013-12-10

Phase 3

Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis

CompletedNCT04142749

PharmaKingNon-Alcoholic Fatty Liver Disease

Start: 2019-11-15End: 2022-09-26Updated: 2022-10-06

Related Papers

Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha‐inhibitory dithiolethione in patients with non‐alcoholic fatty liver disease

Alimentary Pharmacology & Therapeutics2017-02-2272 citations